Drugs / Ficlatuzumab
Trials 14 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 17 trials | ||||||
| Phase 1 | NCT03316599 | Jan 2018 → Oct 2020 | pancreatic ductal adenocarcinoma | Dana-Farber Cancer Institute | Completed | No outcome recorded |
| Phase 1 | NCT02277184 | Sep 2015 → Sep 2016 | head and neck squamous cell carcinoma | Julie E. Bauman, MD, MPH | Terminated | No outcome recorded |
| Phase 1 | NCT02277197 | Aug 2015 → Jun 2016 | head and neck squamous cell carcinoma | James J Lee | Completed | No outcome recorded |
| Phase 1 | NCT02109627 | May 2015 → Dec 2019 | acute myeloid leukemia | C. Babis Andreadis | Terminated | No outcome recorded |
| Phase 1 | NCT01189513 | Aug 2010 → Jan 2011 | glioblastoma | M.D. Anderson Cancer Center | Withdrawn | No outcome recorded |
| Phase 1 | NCT00969410 | Aug 2009 → Mar 2011 | cancer | AVEO Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT00725634 | Sep 2008 → Dec 2010 | plasma cell myeloma | AVEO Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT03013998 | Nov 2016 → Dec 2028 expected | acute myeloid leukemia | Beat AML, LLC | Recruiting | No outcome recorded |
| Phase 1/2 | NCT01039948 | Dec 2009 → Aug 2013 | non-small cell lung carcinoma | AVEO Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT04100330 | Jan → Mar 2020 | acute myeloid leukemia | AVEO Pharmaceuticals, Inc. | Withdrawn | No outcome recorded |
| Phase 2 | NCT03422536 | Dec 2017 → Mar 2022 | basaloid carcinoma, cancer of unknown primary site, lip and oral cavity squamous cell carcinoma, nasal cavity and paranasal sinus squamous cell carcinoma +2 | University of Arizona | Completed | No outcome recorded |
| Phase 2 | NCT02318368 | Nov 2014 → Jan 2017 | non-small cell lung carcinoma | AVEO Pharmaceuticals, Inc. | Terminated | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT06064877 | Jan 2024 → Aug 2027 expected | head and neck squamous cell carcinoma | AVEO Pharmaceuticals, Inc. | Recruiting | No outcome recorded |
| Phase not stated1 trial | ||||||
| — | NCT02090127 | — | malignant mixed neoplasm | AVEO Pharmaceuticals, Inc. | No longer available | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 15 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ficlatuzumab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03013998 ↗ |
| Known as | AV-299 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00725634 ↗ |
| Known as | SCH 900105 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01189513 ↗ |
| Action | Inhibit | “HGF inhibitory monoclonal antibody” PMID 29346833 ↗ Jan 2018 |
| Modality | Monoclonal antibody | “AV-299 is a humanized anti-HGF IgG1 monoclonal antibody” NCT01039948 ↗ |
| Route | Intravenous | “AV-299 monotherapy will be given as intravenous infusion” NCT00725634 ↗ |
| Target | HGF | “directed against free HGF” NCT01039948 ↗ |